Sumitomo Life Insurance Co. Sells 1,622 Shares of Synopsys, Inc. $SNPS

Sumitomo Life Insurance Co. cut its position in shares of Synopsys, Inc. (NASDAQ:SNPS) by 19.5% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 6,715 shares of the semiconductor company’s stock after selling 1,622 shares during the period. Sumitomo Life Insurance Co.’s holdings in Synopsys were worth $3,313,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in SNPS. Stanley Laman Group Ltd. grew its holdings in shares of Synopsys by 542.9% in the third quarter. Stanley Laman Group Ltd. now owns 12,877 shares of the semiconductor company’s stock worth $6,353,000 after purchasing an additional 10,874 shares during the last quarter. Symphony Financial Ltd. Co. boosted its position in Synopsys by 4,780.9% in the 2nd quarter. Symphony Financial Ltd. Co. now owns 40,219 shares of the semiconductor company’s stock valued at $20,638,000 after buying an additional 39,395 shares during the period. Bank of New York Mellon Corp grew its stake in Synopsys by 0.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 1,347,887 shares of the semiconductor company’s stock worth $691,035,000 after acquiring an additional 4,815 shares in the last quarter. Waverton Investment Management Ltd increased its position in shares of Synopsys by 15.0% during the second quarter. Waverton Investment Management Ltd now owns 578,299 shares of the semiconductor company’s stock worth $296,630,000 after acquiring an additional 75,374 shares during the period. Finally, Strategic Advisors LLC increased its position in shares of Synopsys by 76.3% during the third quarter. Strategic Advisors LLC now owns 7,578 shares of the semiconductor company’s stock worth $3,739,000 after acquiring an additional 3,279 shares during the period. 85.47% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. Piper Sandler lowered Synopsys from an “overweight” rating to a “neutral” rating and lowered their price target for the company from $602.00 to $520.00 in a report on Tuesday, January 13th. Morgan Stanley reiterated an “overweight” rating on shares of Synopsys in a report on Wednesday. JPMorgan Chase & Co. increased their price target on Synopsys from $600.00 to $650.00 and gave the stock an “overweight” rating in a research report on Thursday, December 11th. Citigroup started coverage on Synopsys in a report on Monday, November 24th. They issued a “buy” rating and a $580.00 price objective for the company. Finally, The Goldman Sachs Group set a $600.00 target price on shares of Synopsys and gave the stock a “buy” rating in a report on Wednesday. Nine equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $547.00.

Synopsys News Roundup

Here are the key news stories impacting Synopsys this week:

• Positive Sentiment: Q1 results beat consensus — revenue jumped ~65.6% YoY to $2.409B and non‑GAAP EPS of $3.77 topped estimates; company reiterates full‑year revenue midpoint and provided robust FY and Q2 EPS ranges. Synopsys Posts Financial Results for First Quarter Fiscal Year 2026
• Positive Sentiment: Board authorized a replenishment of the repurchase program (up to $2.0B), supporting shareholder returns and offsetting some integration anxieties. Synopsys Posts Financial Results for First Quarter Fiscal Year 2026
• Positive Sentiment: Some analysts remain constructive — Morgan Stanley maintained a Buy and analysts call out solid earnings quality and IP trajectory as catalysts. Synopsys: Strong Earnings Quality … Support Buy Rating
• Neutral Sentiment: Notable option activity — unusually large call buying suggests elevated speculative interest/positioning into or after the print (could magnify intraday moves).
• Negative Sentiment: Guidance and China exposure concerns: Reuters reports Synopsys flagged a more muted near‑term outlook tied to China export restrictions and macro uncertainty, which pressured the stock despite the beat. Synopsys forecasts muted quarter on China export restrictions, shares fall
• Negative Sentiment: Debt & integration risk from the large acquisition remains in focus — coverage highlights ~$13.5B in debt and questions about digesting the multibillion acquisition, keeping some investors cautious. Synopsys Carries $13.5 Billion in Debt Into Its Most Consequential Earnings Yet
• Negative Sentiment: Market reaction: several reports note SNPS “slid” despite the beat — investors appear to be weighing forward risks (China, deal debt/integration) more heavily than the quarter’s upside. Synopsys slides despite Q1 results demonstrating 65% revenue surge

Synopsys Stock Up 1.9%

NASDAQ:SNPS opened at $449.17 on Thursday. The company’s 50-day simple moving average is $472.85 and its 200-day simple moving average is $479.02. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.52 and a current ratio of 1.62. Synopsys, Inc. has a fifty-two week low of $365.74 and a fifty-two week high of $651.73. The stock has a market capitalization of $86.04 billion, a P/E ratio of 56.22, a P/E/G ratio of 3.67 and a beta of 1.12.

Synopsys (NASDAQ:SNPS) last posted its quarterly earnings data on Wednesday, February 25th. The semiconductor company reported $3.77 earnings per share for the quarter, topping analysts’ consensus estimates of $3.56 by $0.21. The firm had revenue of $2.41 billion during the quarter, compared to analysts’ expectations of $2.39 billion. Synopsys had a return on equity of 7.89% and a net margin of 18.89%.The business’s quarterly revenue was up 65.6% on a year-over-year basis. During the same quarter last year, the firm earned $3.03 EPS. Synopsys has set its FY 2026 guidance at 14.380-14.460 EPS and its Q2 2026 guidance at 3.110-3.170 EPS. On average, equities analysts anticipate that Synopsys, Inc. will post 10.64 earnings per share for the current fiscal year.

Insider Activity

In other news, CFO Shelagh Glaser sold 3,657 shares of the company’s stock in a transaction on Friday, December 19th. The shares were sold at an average price of $460.77, for a total value of $1,685,035.89. Following the sale, the chief financial officer directly owned 17,842 shares of the company’s stock, valued at $8,221,058.34. This represents a 17.01% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Janet Lee sold 250 shares of the stock in a transaction on Monday, January 12th. The stock was sold at an average price of $530.00, for a total transaction of $132,500.00. Following the completion of the sale, the insider owned 11,959 shares in the company, valued at $6,338,270. The trade was a 2.05% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 4,157 shares of company stock valued at $1,945,036. Company insiders own 0.62% of the company’s stock.

About Synopsys

Synopsys, Inc is a leading provider of electronic design automation (EDA) software and semiconductor intellectual property (IP) used to design, verify and manufacture integrated circuits and complex systems-on-chip (SoCs). Its product portfolio spans tools and technologies for front‑end design and synthesis, simulation and verification, physical implementation and signoff, and design-for-manufacturability, enabling chip designers to move from architecture through tape‑out.

In addition to core EDA offerings, Synopsys supplies a broad set of semiconductor IP building blocks — such as interface, memory and analog/mixed-signal cores — that customers integrate into SoCs to accelerate development.